Non-Valvular Atrial Fibrillation (NVAF)
Conditions
Keywords
BMS-562247, Apixaban, Atrial fibrillation, Oral Anticoagulants, Japan, Retrospective Study
Brief summary
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
Interventions
None listed
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
• Participants received medical treatment for NVAF between 10-Jan-2012 and 31-Aug-2020.
Exclusion criteria
* Had no data of serum creatinine in the participant's medical records * Had no data of body weight in the participant's medical records * Were given oral anticoagulant (OAC) for treatment of diseases other than atrial fibrillation (AF) Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Specialization of the treating physician | At Baseline |
| Distribution of socio-demographic characteristics of NVAF participants: Age group | At Baseline |
| Distribution of socio-demographic characteristics of NVAF participants: Gender | At Baseline |
| Distribution of socio-demographic characteristics of NVAF participants: Body weight | At Baseline |
| Distribution of socio-demographic characteristics of NVAF participants: Height | At Baseline |
| Distribution of socio-demographic characteristics of NVAF participants: Body mass index (BMI) | At Baseline |
| Distribution of outcomes of NVAF participants: Drinking information | At Baseline |
| Distribution of outcomes of NVAF participants: Smoking information | At Baseline |
| Distribution of outcomes of NVAF participants: Internal medical device information | At Baseline |
| Distribution of outcomes of NVAF participants: Degree of life freedom | At Baseline |
| Distribution of outcomes of NVAF participants: Hospitalization/outpatient status | At Baseline |
| Distribution of outcomes of NVAF participants: Systolic and diastolic blood pressure | At Baseline |
| Distribution of outcomes of NVAF participants: Pulse rate | At Baseline |
| Distribution of clinical characteristics of NVAF participants: Risk factors for stroke | At Baseline |
| Distribution of clinical characteristics of NVAF participants: Risk factors for bleeding | At Baseline |
| Distribution of clinical characteristics of NVAF participants: Comorbidities | At Baseline |
| Distribution of outcomes of NVAF participants: OAC prescription and administration status | At Baseline |
| Distribution of medication prescribed during baseline: angiotensin-converting enzyme inhibitor (ACE) | At Baseline |
| Distribution of medication prescribed during baseline: angiotensin-receptor blocker (ARB) | At Baseline |
| Distribution of medication prescribed during baseline: calcium antagonist | At Baseline |
| Distribution of medication prescribed during baseline: Antiarrhythmic drug | At Baseline |
| Distribution of medication prescribed during baseline: Statin | At Baseline |
| Distribution of medication prescribed during baseline: proton pump inhibitor (PPI) | At Baseline |
| Distribution of medication prescribed during baseline: H2-receptor antagonist | At Baseline |
| Distribution of medication prescribed during baseline: aspirin | At Baseline |
| Distribution of medication prescribed during baseline: P2Y12 inhibitor | At Baseline |
| Distribution of medication prescribed during baseline: Other antiplatelet drugs | At Baseline |
| Distribution of medication prescribed during baseline: Other anticoagulants | At Baseline |
| Distribution of medication prescribed during baseline: P-glycoprotein inhibitor | At Baseline |
Countries
Japan
Outcome results
None listed